Table 2.

Within-treatment marijuana use outcomes by treatment condition and a priori contrasts.

		CBTalone	CBT + CMadher	CBT + CM abst	CMabst	Total	Contrast 1 CBT + CMadher versus CBTalone		Contrast 2 CBT + CMabst versus CM abst		Contrast 3 CBTalone versus CBT + CMadher, CBT + CMabst, CMabst
Variable		n = 36	n = 32	n = 32	n = 27	n = 127	F	P	F	P	F	P
Percentage of marijuana-positive urine specimens	Mean	73.1	75.6	75.5	57.1	70.9	0.38	0.74	2.25	0.02	0.67	0.55
	SD	31.2	23.2	29.9	38.4	31.3
Max. consecutive marijuana-negative urine specimens	Mean	2.14	1.59	1.41	3.3	2.06	0.73	0.47	2.33	0.02	0.08	0.94
	SD	3.57	1.92	2.65	3.91	3.13
Max. consecutive days abstinent (84 days max.)	Mean	35.8	33.9	28.8	33.8	33.2	1.5	0.79	0.65	0.52	0.62	0.54
	SD	29.8	23.7	30.5	30.5	28.5
Percentage cannabis-using days using by self-report	Mean	35.6	34.4	49.3	31.9	38.1	0.1	0.89	1.7	0.07	0.43	0.69
	SD	36.2	31.1	37.2	38.0	35.9

CBT: cognitive–behavioral therapy; CM: contingency management; SD: standard deviation.